58 results found.
Revenue Review: 3Q18 Performance Highlights and 2018 Projections for Public Companies, Continued
By Mike Evers In the exhibits below, we've added nine companies to round out our revenue review for 3Q18. As noted in last month's 
Xtant Reports 3Q18 Revenue of $17.3MM, -12.7% vs. 3Q17
Xtant reports 3Q18 revenue of US $17.3MM, -12.7% vs. 3Q17.
Public Orthopaedic Companies: 1Q18 Revenue and Growth Drivers
By Julie A. Vetalice The 21 companies tracked in Exhibits 1 and 2 collectively grew +3.1% in 1Q18 vs. 1Q17, remaining on track alongside our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. (Review
Xtant Medical Expands Cervical Portfolio with First Porous Titanium Implant
Xtant Medical received FDA 510(k) clearance for its InTice™-C Porous Titanium Cervical Interbody System.
Xtant Medical Posts 1Q18 Revenue
Xtant Medical posted 1Q18 revenue of US $17.9MM, -18.8% vs. 1Q17.
curasan Enters Distribution Agreement with Implantcast
curasan entered into an exclusive agreement with Implantcast for distribution of CERASORB bone regeneration produc...
Xtant Medical Reports 3Q17 Revenue
Xtant Medical posted 3Q17 revenue of US $19.8MM, -14.3% vs. 3Q16, with YTD revenue of $63.3MM, -3.4% vs. the...
Xtant Medical and curasan Enter Distribution Agreement
Xtant Medical entered the U.S. bone graft substitute market through a distribution agreement with curasan...
Sites Medical and Integrity Implants Enter License Agreement
Sites Medical entered into an agreement to license OsteoSync™ Ti technology to Integrity Implants
Xtant Medical Receives FDA Clearance for Expanded Indications of Irix-A
Xtant Medical received FDA 510(k) clearance to market line extensions for the Irix-A standalone interbody...
Sales Results for 20 Orthopaedic Companies: A Mid-year Status Report
By Julie A. Vetalice Now that we’ve collected 1H17 results from 20 publicly-traded companies, I’d like to share some performance-based observations. With now just 4 months remaining in the year, these companies provide a helpful gauge in projecting industry growth.
Xtant Medical Posts 20.5% Orthobiologics Growth in 2Q17
Xtant Medical posted 2Q17 revenue of US $21.4MM, -0.3% vs. 2Q16, with 1H17 revenue of $43.5MM, +2....
Xtant Medical Receives Additional FDA Clearance for Calix-C Cervical Interbody Cages
Xtant Medical received FDA 510(k) clearance for additional sizes of Calix-C™ cerv...
Public and Private Company Revenue Review: 1Q17
By Julie A. Vetalice We're eager to see 2Q17 results to prepare a 1H review for you. In the interim, here are the 1Q17 numbers for publicly-traded companies, with updates and estimates for a number of privately-traded companies, too. Exhibits 1 and 2 illustrate 1Q17 performanc...
Strategic orthopaedic-related 510(k)s issued in May 2017
Strategic orthopaedic-related 510(k)s issued in May 2017 include: Locking Plate System (Beijing KeYi Medical Device), Collagen Meniscus Implant XL (
Xtant Medical 1Q17 Revenue
Xtant Medical posted 1Q17 revenue of US $22.1MM, +5.3% vs. 1Q16.
Xtant Medical to License Sites Medical OsteoSync Ti Technology
Xtant Medical (XTNT) entered into a licensing agreement with Sites Medical for use of OsteoSync™ Ti ...
Company Revenue 2016
For these publicly-traded orthopaedic device companies, Exhibits 1 and 2 present 2016 orthopaedic revenue and growth. Exhibit 1 includes links to company's full-year revenue reporting, as well. ...
Xtant Medical Posts 4Q16 and 2016 Revenue
Xtant Medical posted 2016 revenue of US $90.0MM, +4.0% vs. 2015, with 4Q16 revenue of $24.5MM, +9.9% v...
Xtant Medical Reports Preliminary 2016/4Q16 Revenue
Xtant Medical announced preliminary 2016 revenue of ~US $90.0MM, with estimated 4Q16 revenue of ~...
Xtant Medical Receives FDA Clearance for Xsert Lumbar Expandable Interbody System
Xtant Medical announced FDA 510(k) clearance to market the Xsert™ Lumbar Expandable Interbody Syste...
Company Revenue 3Q16: A Final Look
By Julie A. Vetalice As we wrap up orthopaedic revenue for the latest reporting period, we observe that Stryker and Zimmer Biomet lead the largest orthopaedic companies in 3Q16 growth:
First Surgical Cases with Xspan Laminoplasty Fixation System
Xtant Medical commenced limited launch and announced first surgical cases for the Xspan™
Xtant Medical Reports 3Q16 Revenue
Xtant Medical posted 3Q16 revenue of US $23.1MM, +10.5% vs. 3Q15.
Company Revenue Update, 1H16
By Julie A. Vetalice We complete our coverage of 1H16 revenue in this issue. Stryker and Smith & Nephew lead the top five in growth, with 1H16 performance in the low-single-digits compared to 1H15. DePuy Synthes and Zimmer Biomet reported
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2018 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group